title: 2-Cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride inhibits microglial activation by suppression of nuclear factor-kappa B and mitogen-activated protein kinase signaling.
abstract: The activation of microglia is crucially associated with the neurodegeneration observed in many neuroinflammatory pathologies, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease. Therefore, the inhibition of microglial activation may alleviate certain neurodegenerative processes. We previously demonstrated the protective actions of a new drug, 2-cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride (KHG26377), against glutamate-induced excitotoxicity and ischemic neuronal damage in in vivo rat brain study. The current investigation explored the possible mechanisms underlying the anti-inflammatory effects of this compound against lipopolysaccharide (LPS)-stimulated activation of cultured BV-2 microglial cells. The results showed that KHG26377 reduced the production of prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), reactive oxygen species (ROS), and nitric oxide (NO) in LPS-activated microglia. Furthermore, KHG26377 attenuated LPS-mediated increases in the protein expression levels of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), toll-like receptor 4 (TLR4), phosphorylated extracellular signal-regulated kinase (p-ERK), and phosphorylated p38 mitogen-activated protein kinase (p-p38 MAPK). The compound also prevented the LPS-provoked translocation of the nuclear factor-kappa B (NF-κB) p65 subunit (NF-κB-p65) from the cytosol into the nucleus of BV-2 cells. These findings suggest that KHG26377 may find utility as a therapeutic agent that can be further developed for the management of various neuroinflammatory conditions.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, Seoul, 138-736, South Korea.
authors.forename: Eun-A
authors.initials: EA
authors.lastname: Kim
authors.forename: Jiyoung
authors.initials: J
authors.lastname: Choi
authors.forename: A Reum
authors.initials: AR
authors.lastname: Han
authors.forename: Chang Hun
authors.initials: CH
authors.lastname: Cho
authors.forename: Soo Young
authors.initials: SY
authors.lastname: Choi
authors.forename: Jee-Yin
authors.initials: JY
authors.lastname: Ahn
authors.forename: Sung-Woo
authors.initials: SW
authors.lastname: Cho
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D015232:Dinoprostone / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D051379:Mice; D017628:Microglia / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D019950:Mitogen-Activated Protein Kinase 1 / Q000096:biosynthesis; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis; D010766:Phosphorylation; D017382:Reactive Oxygen Species; D013844:Thiazoles / Q000494:pharmacology*; D051197:Toll-Like Receptor 4 / Q000096:biosynthesis; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000096:biosynthesis
chemical_list: C550808:2-cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D017382:Reactive Oxygen Species; D013844:Thiazoles; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D019950:Mitogen-Activated Protein Kinase 1; D048051:p38 Mitogen-Activated Protein Kinases; D015232:Dinoprostone
references.citation: J Neuroinflammation. 2010 May 19;7:30
references.pmid: 20482831
references.citation: Brain Res Mol Brain Res. 2005 Oct 31;140(1-2):45-54
references.pmid: 16153742
references.citation: BMB Rep. 2013 Dec;46(12):617-22
references.pmid: 24195795
references.citation: BMB Rep. 2012 Mar;45(3):147-52
references.pmid: 22449700
references.citation: Adv Clin Chem. 1998;33:55-131
references.pmid: 10086175
references.citation: Cell Mol Neurobiol. 2010 Jul;30(5):807-15
references.pmid: 20198420
references.citation: CNS Neurosci Ther. 2008 Fall;14(3):215-26
references.pmid: 18801114
references.citation: Food Chem Toxicol. 2014 Jan;63:119-27
references.pmid: 24211520
references.citation: BMB Rep. 2013 Jul;46(7):352-7
references.pmid: 23884101
references.citation: Chem Pharm Bull (Tokyo). 2005 Apr;53(4):410-8
references.pmid: 15802841
references.citation: Immunol Lett. 2005 Feb 15;97(1):101-6
references.pmid: 15626481
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4668-73
references.pmid: 10200320
references.citation: Neurobiol Aging. 2000 May-Jun;21(3):383-421
references.pmid: 10858586
references.citation: Curr Top Microbiol Immunol. 2002;270:81-92
references.pmid: 12467245
references.citation: J Neuroimmunol. 2002 Nov;132(1-2):18-24
references.pmid: 12417429
references.citation: Neuropharmacology. 2011 Sep;61(4):592-9
references.pmid: 21575647
references.citation: J Neurochem. 1992 Sep;59(3):897-905
references.pmid: 1379633
references.citation: Eur J Pharmacol. 2007 Dec 8;576(1-3):151-9
references.pmid: 17698059
references.citation: Prog Neurobiol. 2005 Jun;76(2):77-98
references.pmid: 16081203
references.citation: Neurotoxicology. 2013 Sep;38:106-14
references.pmid: 23867830
references.citation: J Med Chem. 1995 Jan 20;38(2):353-8
references.pmid: 7830278
references.citation: Nature. 1994 Dec 22-29;372(6508):739-46
references.pmid: 7997261
references.citation: Prog Neurobiol. 2002 Jun;67(2):161-72
references.pmid: 12126659
references.citation: J Neuroimmunol. 2001 Jul 2;117(1-2):87-96
references.pmid: 11431008
references.citation: J Neurosci. 1998 Mar 1;18(5):1633-41
references.pmid: 9464988
references.citation: Exp Mol Med. 2007 Dec 31;39(6):715-21
references.pmid: 18160842
references.citation: BMB Rep. 2013 Jun;46(6):316-21
references.pmid: 23790975
references.citation: Glia. 2002 Nov;40(2):175-83
references.pmid: 12379905
references.citation: BMB Rep. 2012 Oct;45(10):583-8
references.pmid: 23101513
references.citation: BMB Rep. 2013 Jul;46(7):370-5
references.pmid: 23884104
references.citation: BMB Rep. 2013 Aug;46(8):398-403
references.pmid: 23977987